IL-1R2 Protein, Cynomolgus (HEK293, Fc)

IL-1R2 is a competitive endogenous inhibitor of IL-1 signaling. IL-1R2 serves as a decoy receptor and competes with IL-1R1 for IL-1, it can also form a complex with IL-1RAP once it binds IL-1. IL-1R2 is implicated in various IL-1-mediated inflammatory diseases^[1]. IL-1R2 Protein, Cynomolgus (HEK293, Fc) is a recombinant cynomolgus IL-1R2 protein with an hFc tag at the C-terminus and is expressed in HEK293 cells. It consists of 343 amino acids (M1-E343).

IL-1R2 is the non-signaling type 2 interleukin-1 receptor and is natively found on neutrophils, B-cells, monocytes and macrophages. IL-1R2 can be cleaved into two forms: membrane form and soluble form.
The sequence of amino acids in IL-1R2 from cynomolgus shows low similarity (about 60%) with both mouse and rat IL-1R2, but shows very high similarity with human IL-1R2 (95.43%).
IL-1R2 contains truncated cytoplasmic domain and lacks Toll-IL-1 receptor (TIR) region, making it incapable of transmembrane signaling. IL-1R2 serves as an endogenous inhibitor of IL-1 signaling. Functional IL-1 signaling requires IL-1R1 and IL-1-dependent recruitment of IL-1RAP. IL-1R2 serves as a decoy receptor and can compete with IL-1R1 for IL-1. IL-1R2 can also form a complex with IL-1RAP once it binds IL-1, preventing IL-1RAP from heterodimerizing with IL-1R1. Through these 2 ways, IL-1R2 blocks IL-1 signaling. Additionally, soluble IL-1R2 recruits soluble IL-1RAP with high affinity without impacting affinity for IL-1RA.
IL-1R2 inhibits IL-1 signaling and has been implicated in various IL-1-mediated inflammatory diseases like arthritis, diabetes, gout and so on^[1][2][3].

Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus IL-1R2 at 10 μg/mL (100 μL/well) can bind biotinylated human IL1B. The ED₅₀ for this effect is 36.13 ng/mL.

• 
  Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus IL-1R2 at 10 μg/mL (100 μL/well) can bind biotinylated human IL1B. The ED₅₀ for this effect is 36.13 ng/mL.

Cynomolgus

HEK293

C-hFc

Q8HXR9 (F14-E343)

711638  [NCBI]

Partial

FTLQPAAHTGAARSCRFRGRHYKREFRLEGEPVALRCPQVPYRLWASVSPHINLTWHKNDSARMVPGEEETRMWAQDGALWLLPALQEDSGTYICTTRNASYCDKVSIELRVFENTDASLPFISYPQILTLSTSGVLVCPDLREFTRDKTDVKIQWYKDSLPLDKDNEKFLSVRGTTHLLVHDVALEDAGYYRCVLTFAHEGQQYNITRTVELRIKKKKEETIPVIISPLKTISASLGSRLTIPCKVFLGTGTPLTTMLWWTANDTHVESAYPGGRVTEGPRQEYSENNENYIEVPLIFDPVTREDLNMDFKCVVRNTLGFQTLRTTVKE

Approximately 80-95 kDa

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. PetersVA,etal.IL-1receptor2(IL-1R2)anditsroleinimmuneregulation.BrainBehavImmun.2013Aug;32:1-8.  [Content Brief]

  [2]. Molgora M, et al. Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8. Immunol Rev. 2018 Jan;281(1):233-247.  [Content Brief]

  [3]. Lin J, et al. Cardiomyocyte IL-1R2 protects heart from ischemia/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis. Cell Death Dis. 2022 Jan 27;13(1):90.  [Content Brief]